摘要
目的:评价苯磺酸左旋氨氯地平联合缬沙坦治疗原发性高血压的临床疗效及安全性。方法:选取2010年5月-2012年5月在本院门诊就诊的130例原发性高血压患者,按照随机数字表法将其分为对照组和观察组各65例,对照组给予每日口服2.5 mg苯磺酸左旋氨氯地平,观察组在对照组的基础上,每日加服80 mg缬沙坦,两组患者中若治疗1周后,患者血压未恢复不理想,可使口服苯磺酸左旋氨氯地平剂量增至5 mg,缬沙坦剂量增至160 mg,连续治疗6周。对两组患者治疗效果及不良反应进行观察比较。结果:两组患者经治疗后,收缩压及舒张压均明显低于治疗前,差异均有统计学意义(P<0.05);且治疗组患者的收缩压及舒张压降低差值与对照组比较差异无统计学意义(P>0.05)。同时,经治疗后,观察组的总有效率96.9%明显高于对照组的84.6%,差异有统计学意义(P<0.05)。两组患者在治疗过程中无严重不良反应。结论:原发性高血压患者采用苯磺酸左旋氨氯地平联合缬沙坦进行治疗能有效地对血压情况进行改善,与单用苯磺酸左旋氨氯地平比较,治疗效果更好,值得临床推广应用。
Objective：To evaluate the clinical efficacy and security of Levamlodipine besylate combined with Valsartan in the treatment of primary hypertension.Method：130 patients with primary hypertension in our hospital were selected from May 2010 to May 2012,they were divided into the control group and the observation group randomly,65 cases in each group,the control group was given oral Levamlodipine besylate 2.5 mg one day,while the observation group was given oral Valsartan 80 mg one day on the basis of the control group.The Levamlodipine besylate and Valsartan dose reached to 5 mg and 160 mg respectively if the efficacy was not good after one week′s treatment.The adverse reactions and clinical efficacy of the two groups were observed and compared.Result：Systolic and diastolic pressure of patients in the two groups after treatment were lower than before treatment significantly,the differences were statistically significant（P〈0.05）,there were no significant difference between control and observation group after treatment（P〈0.05）.The total efficacy of the observation group was 96.9%,it was significantly higher than the 84.6% of control group,the difference was statistically significant（P〈0.05）.There were no adverse reactions in both groups.Conclusion：Levamlodipine besylate combined with Valsartan is more efficient than single Levamlodipine besylate to decrease blood pressure in the treatment of primary hypertension,is worthy of promotion.
出处
《中国医学创新》
CAS
2014年第6期91-93,共3页
Medical Innovation of China
